Ovid Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results and announced topline safety, tolerability and pharmacokinetics findings from the 7 mg dose cohort of OV329, its next generation GABA-aminotransferase inhibitor. Also, the company priced a $60 million private placement.